Onuki Mamiko, Matsumoto Koji, Tenjimbayashi Yuri, Tasaka Nobutaka, Akiyama Azusa, Sakurai Manabu, Minaguchi Takeo, Oki Akinori, Satoh Toyomi, Yoshikawa Hiroyuki
Department of Obstetrics and Gynecology, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan.
Department of Obstetrics and Gynecology, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan.
Papillomavirus Res. 2018 Dec;6:41-45. doi: 10.1016/j.pvr.2018.10.005. Epub 2018 Oct 19.
The prognostic impact of human papillomavirus (HPV) type on invasive cervical cancer (ICC) was analyzed for 137 women treated for ICC at a single institution between 1999 and 2007. The study subjects were divided into three groups according to HPV genotype: HPV16-positive (n = 59), HPV18-positive (n = 33), and HPV16/18-negative ICC (non-HPV16/18, n = 45). The median follow-up time was 102.5 months (range, 5-179). The 10-year overall survival (10y-OS) rates in women with FIGO stage I/II disease were similar among HPV genotypes: 94.7% for HPV16 (n = 39), 95.2% for HPV18 (n = 26), and 96.4% for non-HPV16/18 (n = 29). However, the 10y-OS rates in women with FIGO stage III/IV tumors were 73.7% for HPV16 (n = 20), 45.7% for HPV18 (n = 7), and 35.7% for other types (n = 16), with significantly higher survival in HPV16-positive compared with HPV16-negative ICC (10y-OS; 73.7% vs. 39.5%, P = 0.04). This difference in FIGO stage III/IV tumors remained significant after adjusting for age and histology (hazard ratio 0.30, 95% confidence interval 0.09-0.86, P = 0.02). These results suggest that detection of HPV16 DNA may be associated with a favorable prognosis in patients with FIGO stage III/IV ICC. Given that most women with FIGO stage III/IV tumors received concurrent chemoradiotherapy, this finding may imply that HPV16-positive tumors are more chemoradiosensitive.
对1999年至2007年期间在一家机构接受浸润性宫颈癌（ICC）治疗的137名女性，分析了人乳头瘤病毒（HPV）类型对ICC的预后影响。研究对象根据HPV基因型分为三组：HPV16阳性（n = 59）、HPV18阳性（n = 33）和HPV16/18阴性ICC（非HPV16/18，n = 45）。中位随访时间为102.5个月（范围5 - 179个月）。FIGO I/II期疾病女性的10年总生存率（10y - OS）在各HPV基因型中相似：HPV16为94.7%（n = 39），HPV18为95.2%（n = 26），非HPV16/18为96.4%（n = 29）。然而，FIGO III/IV期肿瘤女性的10y - OS率，HPV16为73.7%（n = 20），HPV18为45.7%（n = 7），其他类型为35.7%（n = 16），HPV16阳性ICC的生存率显著高于HPV16阴性ICC（10y - OS；73.7%对39.5%，P = 0.04）。在调整年龄和组织学后，FIGO III/IV期肿瘤的这种差异仍然显著（风险比0.30，95%置信区间0.09 - 0.86，P = 0.02）。这些结果表明，检测到HPV16 DNA可能与FIGO III/IV期ICC患者的良好预后相关。鉴于大多数FIGO III/IV期肿瘤女性接受了同步放化疗这一发现可能意味着HPV16阳性肿瘤对放化疗更敏感。
